|
|
|
|
|
|
Sponsored by: |
Hospital Universitario Dr. Jose E. Gonzalez |
Information provided by: | Hospital Universitario Dr. Jose E. Gonzalez |
ClinicalTrials.gov Identifier: | NCT00730561 |
Several pathophysiological theories have been proposed for the development of diabetic chronic complications. In recent years, the use of stem cells (totipotential, hematopoietic or endothelial lineages) has been reported as an adjunctive modality of treatment for ischemia models in animals and humans. Nevertheless, there are no reports in the use of stem cells for the treatment of human sensorimotor peripheral diabetic neuropathy. We performed this study to evaluate the effect of autologous hematopoietic CD34+ cell transplantation on nerve conduction velocity in patients with type 2 diabetes mellitus.
Condition | Intervention |
Limb Ischemia Diabetic Neuropathy |
Biological: Hematopoietic stem cell transplantation |
MedlinePlus related topics: | Diabetes Diabetic Nerve Problems |
Drug Information available for: | Filgrastim |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy in Patients With Diabetes Mellitus Type 2:A Randomized Controlled Trial. |
Enrollment: | 20 |
Study Start Date: | March 2006 |
Study Completion Date: | December 2007 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: No Intervention | |
2: Experimental
Hematopoietic stem cell transplantation
|
Biological: Hematopoietic stem cell transplantation
Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
|
Ages Eligible for Study: | 18 Years to 74 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Mexico, Nuevo León | |||||
Hospital Universitario "José E. González" | |||||
Monterrey, Nuevo León, Mexico, 64460 |
Hospital Universitario Dr. Jose E. Gonzalez |
Principal Investigator: | Fernando J Lavalle, MD | Departamento de Endocrinología del Hospital Universitario "José E. González" |
Responsible Party: | Departamento de Endocrinologia ( Fernando Javier Lavalle Gonzalez ) |
Study ID Numbers: | Endo01 |
First Received: | July 31, 2008 |
Last Updated: | August 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00730561 |
Health Authority: | Mexico: National Institute of Public Health, Health Secretariat |
|
|
|
|